Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled time : 22:00    source : Www.biospace.com    save search
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
Published: 2024-04-24 (Crawled : 22:00) - biospace.com/
PLSE | $6.86 0.0% 130K twitter stocktwits trandingview |
Health Technology
 | | O: 0.87% H: 0.14% C: -0.87%
first conference for financial results
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
Published: 2024-04-24 (Crawled : 22:00) - biospace.com/
RCUS 4 | $15.43 -0.45% 0.0% 520K twitter stocktwits trandingview |
Health Technology
 | | O: -0.06% H: 2.32% C: -0.39%
asco arcus meeting
Two Clinical Trials Identify a Better Way to Target Appropriate Antibiotics for Patients Hospitalized With Pneumonia or Urinary Tract Infection
Published: 2024-04-19 (Crawled : 22:00) - biospace.com/
FNCTF | News | $11.16 1.13% -20.84% 0 twitter stocktwits trandingview |
Communications
 | Email alert Add to watchlist
infection antibiotics trials for
NanoString Technologies to Be Acquired by Bruker Corporation
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
BRKR | $82.2 -0.32% -0.3% 990K twitter stocktwits trandingview |
Health Technology
 | | O: 0.89% H: 0.0% C: 0.0%
corporation acquired
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
EOLS | $11.5 -1.71% -1.92% 2 twitter stocktwits trandingview |
Health Technology
 | | O: -1.49% H: 0.0% C: 0.0%
jeuveau publication for study
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | $2.45 1.24% 3.2% 8.5K twitter stocktwits trandingview |
Health Technology
 | | O: 4.43% H: 0.0% C: 0.0%
dm199 first stroke treatment for trial therapeutics
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalLack of early symptom improvement is not predictive of final responder status
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
STIM | $3.75 -2.85% -2.66% 21K twitter stocktwits trandingview |
Health Technology
 | | O: 1.18% H: 4.28% C: 1.17%
publication treatment
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
RLYB | News | $1.58 -9.2% -9.43% 250K twitter stocktwits trandingview |
| | O: -3.03% H: 4.38% C: 1.87%
JNJ | News | $148.53 -0.69% 0.18% 7.5M twitter stocktwits trandingview |
Health Technology
 | | O: 0.21% H: 0.0% C: 0.0%
risk solutions for collaboration
Blacksmith Medicines To Highlight Preclinical Oncology Data Demonstrating a Potent and Selective FEN1 Inhibitor Has Synergy with Multiple DDR Drug Classes at AACR Annual Meeting 2024
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M twitter stocktwits trandingview |
Health Technology
 | | O: -0.71% H: 0.0% C: 0.0%
drug preclinical meeting
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
VRTX | $400.76 -1.03% -1.06% 810K twitter stocktwits trandingview |
Health Technology
 | | O: -1.13% H: 0.28% C: -0.58%
ALPN | $64.57 0.03% 0.03% 1 twitter stocktwits trandingview |
Health Technology
 | | O: -2.7% H: 26.26% C: 24.15%
nephropathy sciences
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
NUVB | $2.66 -0.75% -0.38% 1.3M twitter stocktwits trandingview |
| | O: -4.64% H: 1.3% C: -0.97%
acquisition therapeutics
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Published: 2024-04-08 (Crawled : 22:00) - biospace.com/
BPTS | $9.7031 -4.78% -0.39% 3.1K twitter stocktwits trandingview |
Manufacturing
 | | O: -3.31% H: 0.0% C: -4.69%
bio101 obesity study
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-04 (Crawled : 22:00) - biospace.com/
ACLX | $52.82 -2.98% -3.12% 310K twitter stocktwits trandingview |
| | O: -0.13% H: 2.16% C: -1.76%
conference
Biden, Sanders Target Drug Prices at White House Event
Published: 2024-04-03 (Crawled : 22:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M twitter stocktwits trandingview |
Health Technology
 | | O: 0.02% H: 0.0% C: 0.0%
drug house
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
Published: 2024-04-03 (Crawled : 22:00) - biospace.com/
SNGX | $0.383 -4.25% -3.9% 480K twitter stocktwits trandingview |
Health Technology
 | | O: -0.33% H: 3.92% C: -9.85%
design trial agreement
Kyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
Published: 2024-04-02 (Crawled : 22:00) - biospace.com/
AVEO | $15.0 0.0% 0 twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
association presentation research vision meeting
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
Published: 2024-04-02 (Crawled : 22:00) - biospace.com/
MIRM | $24.02 -1.64% -1.75% 320K twitter stocktwits trandingview |
Health Technology
 | | O: -1.3% H: 0.7% C: 0.36%
pruritus positive livmarli
CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements
Published: 2024-04-01 (Crawled : 22:00) - biospace.com/
CNSP | News | $0.214 1.91% -4.9% 4.4K twitter stocktwits trandingview |
Health Technology
 | | O: 6.63% H: 0.0% C: -8.65%
year pharmaceuticals financial results
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
Published: 2024-04-01 (Crawled : 22:00) - biospace.com/
OMER | $3.04 -1.62% -1.64% 250K twitter stocktwits trandingview |
Health Technology
 | | O: -1.16% H: 0.0% C: -6.45%
corporation financial results
Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
Published: 2024-04-01 (Crawled : 22:00) - biospace.com/
ALPN | $64.57 0.03% 0.03% 1 twitter stocktwits trandingview |
Health Technology
 | | O: -0.83% H: 2.52% C: 2.31%
nephropathy congress world sciences
Gainers vs Losers
61% 39%

Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M twitter stocktwits trandingview |

BHIL | $0.1793 -4.37% 19.24% 340K twitter stocktwits trandingview |
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K twitter stocktwits trandingview |

CI | $352.28 -0.11% 13.53% 2 twitter stocktwits trandingview |
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K twitter stocktwits trandingview |
n/a
MTH | $154.69 -2.21% 12.68% 450K twitter stocktwits trandingview |
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 1.2M twitter stocktwits trandingview |

BMTX 4 | $1.545 0.98% 10.03% 2.5K twitter stocktwits trandingview |
Information
TAL | $12.26 0.57% 9.22% 12M twitter stocktwits trandingview |
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M twitter stocktwits trandingview |
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.